CoChat

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

Background Prostate cancer is one of the most prevalent malignancies among men globally. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), primarily used for type 2 diabetes mellitus (T2DM) management, have been investigated for their potential effects on cancer risks. This systematic review and meta-analysis aimed to assess the association between GLP-1 RA use and risk reduction of prostate cancer. Methods A comprehensive literature search was conducted across PubMed, Embase, and Web of Science up to July 30, 2024. Studies that met the inclusion criteria randomized controlled trials, cohort studies, case-control studies, and observational studies assessing the incidence of prostate cancer in GLP-1 RA-treated patients were included. The quality of studies was evaluated using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool. Meta-analysis was performed using a random effects model. Results A total of five studies were included, analyzing data from diverse international contexts. The included studies showed a reduced risk of prostate cancer with both adjusted and unadjusted effect estimates with GLP-1 RAs. The meta-analysis revealed an RR of 0.72 (95% CI: 0.610 to 0.832), indicating a statistically significant 28% reduction in prostate cancer risk associated with GLP-1 RA use compared to placebo or other antidiabetic drugs. Moderate heterogeneity was observed (I 2 = 51%). Sensitivity analysis confirmed the results. Conclusion The findings suggest a significant…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11255-024-04266-4

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 4

  1. De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N (2024) Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review. Thyroid. 34(4):403–18
  2. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:1
  3. Skriver C, Friis S, Knudsen LB, Catarig AM, Clark AJ, Dehlendorff C, Mørch LS (2023) Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia 66(11):2007–2016 · DOI
  4. Stein MS, Kalff V, Williams SG, Murphy DG, Colman PG, Hofman MS (2024) The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. Endocr Oncol. 4:1

Cited by

See all 27

Metadata

Authors
Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., Sharma, G., Kumar, S., Singh, M. P., Bushi, G., Chilakam, N., Pandey, S., Brar, M., Mehta, R., Sah, S., Gaidhane, A. M., & Shabil, M.
Affiliations
  • National Institute of Pharmaceutical Education and Research (IN)
  • Datta Meghe Institute of Higher Education and Research (IN)
  • University of Cyberjaya (MY)
  • Jain University (IN)
  • Vivekananda Global University (IN)
  • NIMS University (IN)
  • Chandigarh University (IN)
  • Uttaranchal University (IN)
  • Graphic Era University (IN)
  • Saveetha University (IN)
  • Lovely Professional University (IN)
  • Noida Institute of Engineering and Technology Pharmacy Institute (IN)
  • Chitkara University (IN)
  • Manav Rachna International Institute of Research and Studies (IN)
  • Dr. D. Y. Patil Medical College, Hospital and Research Centre (IN)
Corresponding author
Shabil, Muhammed
Venue
International Urology and Nephrology
Published
2024-11-04
Volume
57
Issue
4
Pages
1039-1049
ISSN
  • 0301-1623 (ISSN-L)
  • 1573-2584
OpenAlex
W4404026896
Cited by
21
References
26
Citations by year
2026: 10 · 2025: 10 · 2024: 1
FWCI
0.86
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Urology and Nephrology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
GLP-1 receptor agonists, prostate cancer, cancer risk reduction, type 2 diabetes, antidiabetic drugs, chemoprevention, drug repurposing
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Prostatic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s11255-024-04266-4
The paper
Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., Sharma, G., Kumar, S., Singh, M. P., Bushi, G., Chilakam, N., Pandey, S., Brar, M., Mehta, R., Sah, S., . . . Shabil, M. (2024). Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04266-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.